<DOC>
	<DOCNO>NCT02720068</DOCNO>
	<brief_summary>This safety pharmacokinetics study MK-4280 monotherapy combination pembrolizumab ( MK-3475 ) adult metastatic solid tumor available therapy may convey clinical benefit . Part A study dose escalation design participant receive MK-4280 monotherapy MK-4280 combination pembrolizumab . Part B dose confirmation design estimate recommend Phase 2 dose MK-4280 combination pembrolizumab .</brief_summary>
	<brief_title>Study MK-4280 Monotherapy Combination With Pembrolizumab ( MK-3475 ) Adults With Advanced Solid Tumors ( MK-4280-001 )</brief_title>
	<detailed_description />
	<mesh_term>Pembrolizumab</mesh_term>
	<criteria>Part A Has histologically cytologicallyconfirmed metastatic solid tumor available therapy may convey clinical benefit . Has measureable disease immunerelated Response Evaluation Criteria Solid Tumors ( irRECIST ) 1.1 criterion . Has performance status 0 1 Eastern Cooperative Oncology Group ( ECOG ) Performance Scale . Demonstrates adequate organ function If female childbearing potential , willing use adequate method contraception course study 120 day last dose study drug . If male female partner ( ) childbearing potential , must agree use adequate method contraception start first dose study drug 120 day last dose study drug . Males pregnant partner must agree use condom ; additional method contraception require pregnant partner . Must submit evaluable baseline tumor sample analysis ( either recent archival tumor sample ) . Has chemotherapy , radiation biological cancer therapy within 4 week prior first dose study drug , recover Common Terminology Criteria Adverse Events ( CTCAE ) Grade 1 good AEs due cancer therapeutic administer 4 week earlier ( include participant previous immunomodulatory therapy residual immunerelated [ ir ] AEs ) . Is currently participate receive study therapy participate study investigational agent receive study therapy use investigational device within 4 week first dose study drug . Has receive previous treatment another agent target lymphocyteactivation gene 3 ( LAG3 ) receptor . Has receive previous treatment immunomodulatory therapy ( e.g . antiprogrammed cell death protein 1 [ PD1 ] /antiPDligand 1 [ PDL1 ] cytotoxic Tlymphocyteassociated protein 4 [ CTLA 4 ] agent ) discontinue therapy due Grade 3 high irAE . Is expect require form antineoplastic therapy study . Is chronic systemic steroid therapy excess replacement dos , form immunosuppressive medication . Has history previous , additional malignancy , unless potentially curative treatment complete , evidence malignancy 5 year . Time frame exception include successful definitive resection basal cell carcinoma skin , superficial bladder cancer situ cervical cancer , situ cancer . Has know active central nervous system ( CNS ) metastases and/or carcinomatous meningitis . Has severe hypersensitivity reaction treatment another monoclonal antibody . Has active autoimmune disease document history autoimmune disease , except vitiligo resolve childhood asthma/atopy . Has active infection require therapy . Has active , noninfectious pneumonitis . Has prior stem cell bone marrow transplant . Has know history screen positive Human Immunodeficiency Virus ( HIV ) , active chronic acute Hepatitis B Hepatitis C. Has know psychiatric substance abuse disorder would interfere cooperation requirement study . Is regular user determine investigator judgment ( include `` recreational use '' ) illicit drug recent history ( within last year ) substance abuse ( include alcohol ) , time signing informed consent . Has symptomatic ascites pleural effusion . A participant clinically stable follow treatment condition ( include therapeutic thoraco paracentesis ) eligible . For participant receive pembrolizumab : Has interstitial lung disease history pneumonitis require oral IV glucocorticoid assist management . Is pregnant breastfeeding , expect conceive father child within project duration study . Has clinically significant heart disease affect normal activity . Has major surgery past 4 week . Has receive livevirus vaccine within 30 day plan start study drug . Seasonal flu vaccine contain live virus permit .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>February 2017</verification_date>
	<keyword>PD1</keyword>
	<keyword>PD-1</keyword>
	<keyword>PDL1</keyword>
	<keyword>PD-L1</keyword>
</DOC>